Compounds > azelastine

azelastine and mp29-02

azelastine has been researched along with mp29-02 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U1
Bachert, C; Bernstein, J; Bousquet, J; Carr, W; Lieberman, P; Meltzer, E; Munzel, U; Price, D1
Bachert, C; Berger, W; Bousquet, J; Canonica, GW; Carr, W; Hadley, J; Hampel, FC; Lieberman, P; Meltzer, E; Mullol, J; Munzel, U; Murray, R; Price, D; Ratner, P; Scadding, G; Virchow, JC; Wahn, U1
Bachert, C; Bernstein, J; Bousquet, J; Canonica, GW; Carr, W; Dahl, R; Demoly, P; Devillier, P; Fokkens, W; Hellings, P; Klimek, L; Lieberman, P; Meltzer, E; Price, D; Ryan, D; Wahn, U1
Aderhold, C; Birk, R; Häussler, D; Kramer, B; Nastev, A; Sommer, JU; Stuck, BA; Wenzel, A1

Reviews

1 review(s) available for azelastine and mp29-02

ArticleYear
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:6

    Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Drug Combinations; Humans; Phthalazines; Rhinitis, Allergic; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Treatment Outcome

2015

Trials

3 trial(s) available for azelastine and mp29-02

ArticleYear
Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:1

    Topics: Administration, Intranasal; Adolescent; Adult; Androstadienes; Anti-Allergic Agents; Biological Availability; Chromatography, High Pressure Liquid; Drug Combinations; Drug Delivery Systems; Drug Interactions; Female; Fluticasone; Humans; Male; Middle Aged; Nasal Sprays; Phthalazines; Rhinitis, Allergic, Seasonal; Tandem Mass Spectrometry; Young Adult

2012
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.
    The Journal of allergy and clinical immunology, 2012, Volume: 129, Issue:5

    Topics: Administration, Intranasal; Adult; Androstadienes; Disease Progression; Drug Combinations; Female; Fluticasone; Guidelines as Topic; Humans; Male; Middle Aged; Nasal Obstruction; Phthalazines; Rhinitis, Allergic, Seasonal; Seasons; Severity of Illness Index; Young Adult

2012
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
    International archives of allergy and immunology, 2013, Volume: 161, Issue:4

    Topics: Adult; Androstadienes; Anti-Allergic Agents; Cedrus; Disease Progression; Drug Combinations; Female; Fluticasone; Follow-Up Studies; Humans; Male; Middle Aged; Nasal Obstruction; Phthalazines; Rhinitis, Allergic, Seasonal; Severity of Illness Index; Treatment Outcome; Young Adult

2013

Other Studies

1 other study(ies) available for azelastine and mp29-02

ArticleYear
Influence of MP 29-02 on ciliary beat frequency in human epithelial cells in vitro.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018, Volume: 275, Issue:6

    Topics: Administration, Intranasal; Adult; Androstadienes; Drug Combinations; Epithelial Cells; Female; Fluticasone; Humans; In Vitro Techniques; Male; Middle Aged; Nasal Mucosa; Phthalazines; Rhinitis, Allergic, Perennial

2018